<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NPM1-mutated AML &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/npm1-mutated-aml/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 08:58:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>NPM1-mutated AML &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Vascular Issues in NPM1-Mutated Acute Myeloid Leukemia</title>
		<link>https://bioengineer.org/vascular-issues-in-npm1-mutated-acute-myeloid-leukemia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 08:57:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Genetic mutations in leukemia]]></category>
		<category><![CDATA[Individualized medicine]]></category>
		<category><![CDATA[NPM1-mutated AML]]></category>
		<category><![CDATA[Prognostic implications]]></category>
		<category><![CDATA[Thrombotic events]]></category>
		<category><![CDATA[Vascular complications]]></category>
		<guid isPermaLink="false">https://bioengineer.org/vascular-issues-in-npm1-mutated-acute-myeloid-leukemia/</guid>

					<description><![CDATA[Vascular complications in NPM1-mutated acute myeloid leukemia (AML) have emerged as a critical area of research that provides crucial insights into the clinical management of this aggressive hematological malignancy. The study led by Wang et al. sheds light on how specific genetic mutations, particularly those in the NPM1 gene, are intricately linked to the development [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318807</post-id>	</item>
	</channel>
</rss>
